论文部分内容阅读
观察干扰素α— 2b(安达芬 )治疗 1 8周后的慢性乙型肝炎患者肝组织学及血清HBVDNA等变化。采用肝组织损伤程度knodell计分法、免疫组织化学及血清HBVDNA定量检测对 2 2例病人治疗前后进行比较。治疗结束时有 55% ( 1 2 / 2 2 )病人肝组织学活动指数得以改善 (肝组织学活动指数减少≥ 2分 ) ,其中1 6例肝组织炎症活动度 (G)≥ 3者治疗前后肝组织学活动指数有明显降低 (P <0 0 5) ,而G≤ 2的 6例未见显著性差别。免疫组化检测显示治疗后肝组织中HBeAg阴转率为 53 8% ( 7/ 1 3) ,活化的星状细胞数显著减少 (P =0 0 0 0 4 )。血清HBVDNA水平较治疗前明显下降 (P <0 0 1 )。治疗结束HBeAg阴转率为 4 2 9%( 6/ 1 4 )。HBeAg阳性与HBeAg阴性患者相比 ,其肝组织学损伤程度的改善及血清HBVDNA的下降无明显区别。安达芬治疗慢性乙型肝炎可明显降低血清HBVDNA的水平 ,并明显改善其肝组织学的炎症及坏死程度。
Observe the change of liver histology and serum HBVDNA in patients with chronic hepatitis B after interferon α-2b (Andalfarin) treatment for 18 weeks. The degree of liver injury knodell scoring method, immunohistochemistry and serum HBVDNA quantitative detection of 22 patients before and after treatment compared. At the end of treatment, 55% (12/2) of the patients had improved hepatic histological activity index (reduction in hepatic histological activity index ≥ 2 points), of which 16 cases of liver inflammation activity (G) ≥ 3 before and after treatment Liver histological activity index was significantly lower (P <0 05), while G ≤ 2 6 cases no significant difference. The results of immunohistochemistry showed that the negative rate of HBeAg was 53 8% (7/13) and the number of activated stellate cells was significantly decreased (P = 0.00004). Serum HBVDNA levels were significantly lower than before treatment (P <0.01). The negative conversion rate of HBeAg at the end of treatment was 42 29% (6/1 4). HBeAg-positive and HBeAg-negative patients compared to improve the degree of liver damage and serum HBVDNA no significant difference. Andafene treatment of chronic hepatitis B can significantly reduce the level of serum HBVDNA, and significantly improve the degree of liver inflammation and necrosis.